Key Details
Price
$0.70Annual Revenue
$9.15 MAnnual EPS
-$1.81Annual ROE
-723.45%Beta
0.62Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
May 12, 2023Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
The Company received the first $2 million from the ARPA-H Sprint for Women's Health Award The Company received the first $2 million from the ARPA-H Sprint for Women's Health Award
Aspira (AWH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.48 per share a year ago.
Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Nicole Sandford - Chief Executive Officer & Director Sandy Milligan - President John Kallassy - Interim Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Incorporated Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Achieved $141.6 million Net Revenue in Q3 2024 Reported $25.1 million in Adjusted EBITDA Anticipates $30 million of Annual Savings Through Transformation Initiatives MORRISTOWN, N.J. , Nov. 12, 2024 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," or the "Company" or "Ascend") (CSE: AAWH.U) (OTCQX: AAWH), a vertically integrated multi-state cannabis operator focused on bettering lives through cannabis, today reported its financial results for the three months ended September 30, 2024 ("Q3 2024").
Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company's development pipeline Event to feature presentations from Dr. Kevin Elias, Dr. Richard Gersh, Dr. Sandra Milligan, and Dr. Todd Pappas on the Company's development pipeline
Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis
New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State
Aspira Womens Health (AWH, Financial) experienced a significant stock price drop of 7.80%, reaching $0.775 per share. The trading volume stood at 14,064 shares with a turnover rate of 0.09% and a volatility of 7.47%.
AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.
Aspira (AWH) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.28 per share a year ago.
FAQ
- What is the primary business of Aspira Womens Health?
- What is the ticker symbol for Aspira Womens Health?
- Does Aspira Womens Health pay dividends?
- What sector is Aspira Womens Health in?
- What industry is Aspira Womens Health in?
- What country is Aspira Womens Health based in?
- When did Aspira Womens Health go public?
- Is Aspira Womens Health in the S&P 500?
- Is Aspira Womens Health in the NASDAQ 100?
- Is Aspira Womens Health in the Dow Jones?
- When was Aspira Womens Health's last earnings report?
- When does Aspira Womens Health report earnings?
- Should I buy Aspira Womens Health stock now?